The distribution of plasma phenytoin levels in epileptic patients. 1970

P T Lascelles, and R S Kocen, and E H Reynolds

Plasma phenytoin levels were estimated in 111 adult epileptic patients. A wide scatter of values was found, with over half outside the therapeutic limits of 10 to 20 μg/ml. Phenytoin tolerance tests carried out in five patients revealed a possible failure to metabolize the drug adequately in three of them. Factors affecting the plasma phenytoin level are discussed. The importance of this assay is seen in view of the number of patients potentially at risk from toxic blood levels in the absence of accepted clinical manifestations of acute or subacute intoxication.

UI MeSH Term Description Entries
D008297 Male Males
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011324 Primidone A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite. Desoxyphenobarbital,Primaclone,Apo-Primidone,Liskantin,Misodine,Mizodin,Mylepsinum,Mysoline,Primidon Holsten,Resimatil,Sertan,Apo Primidone
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

P T Lascelles, and R S Kocen, and E H Reynolds
January 1977, European neurology,
P T Lascelles, and R S Kocen, and E H Reynolds
August 1982, British journal of clinical pharmacology,
P T Lascelles, and R S Kocen, and E H Reynolds
January 1977, Folia psychiatrica et neurologica japonica,
P T Lascelles, and R S Kocen, and E H Reynolds
January 1979, Folia psychiatrica et neurologica japonica,
P T Lascelles, and R S Kocen, and E H Reynolds
August 1982, Journal of pharmacokinetics and biopharmaceutics,
P T Lascelles, and R S Kocen, and E H Reynolds
January 1977, Folia psychiatrica et neurologica japonica,
P T Lascelles, and R S Kocen, and E H Reynolds
May 1985, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
P T Lascelles, and R S Kocen, and E H Reynolds
January 1990, Brain & development,
P T Lascelles, and R S Kocen, and E H Reynolds
April 1974, British journal of clinical pharmacology,
P T Lascelles, and R S Kocen, and E H Reynolds
May 1978, Journal of neurology, neurosurgery, and psychiatry,
Copied contents to your clipboard!